Bio/Pharma News

Biogen Pays $1.25 Billion to Settle Tecfidera Patent Dispute

January 17, 2017

The company agreed to pay Forward Pharma $1.25 billion to settle a patent dispute over the formulation of Tecfidera, the company’s leading multiple sclerosis treatment.

FDA Guidance on Biosimilar Naming Receives Mixed Response from Industry

January 13, 2017

An FDA guidance on biosimilar naming garnered mixed responses from the Biosimilars Forum, the American College of Rheumatology, and Pfenex.

NIBRT Summarizes Top Trends in the Biopharma Industry

January 11, 2017

Industry experts identify the future focus of the biopharma industry in a new survey.

Gore Releases New Fluoropolymer-Based mAb Purification Technology

January 10, 2017

The membrane-based Protein A purification tool was unveiled at the 2017 PepTalk Conference in San Diego, California.

Astellas Terminates Agreement with UMN Pharma for Influenza Program

January 10, 2017

The company announced that it has terminated an agreement made with UMN Pharma for the co-development of influenza vaccine programs in Japan.

Amgen Links with Immatics to Continue Work on Bispecific T-Cell Therapies

January 09, 2017

The companies will combine expertise on T-cell therapies with two or more binding domains to create novel oncology medications.

PharmaCell to Provide Manufacturing for Orchard Therapeutics’ Gene Therapies

January 09, 2017

UK-based Orchard Therapeutics and PharmaCell ally to support clinical trials and commercialization of Orchard’s ex-vivo gene therapies.

Takeda to Acquire ARIAD

January 09, 2017

Takeda will acquire ARIAD Pharmaceuticals for approximately $5.2 billion.

Do New Cancer Drugs Increase Overall Clinical Benefit?

January 06, 2017

A study of 53 cancer drugs found that new treatments extended patient life an average of 3.43 months when compared with treatments available in 2003.

Regeneron and Sanofi Ordered to Withdraw PCSK9 Inhibitor Praluent from Market

January 06, 2017

A judge ruled that Regeneron’s mAb be removed from the market after Amgen alleged that the marketing of Praluent hurt its reputation as innovator of this class of drugs.